文献速递淋巴瘤

伊布替尼治疗早期慢性淋巴细胞白血病:随机、安慰剂对照、双盲、III期CLL12试验

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
PubMed 文献 · J Clin Oncol · 2024-11-27

德国CLL研究组开展随机双盲安慰剂对照III期试验,363例无症状初治Binet A期高危进展CLL患者随机接受伊布替尼420mg/日(n=182)或安慰剂(n=181),另152例低危患者进入观察等待组。伊布替尼显著延迟进展至症状性疾病(P<.001;HR 0.276 [95%CI 0.188-0.407]),但中位观察69.3个月时26例死亡,未观察到生存获益(P=.562)。结论认为在靶向治疗时代,无论风险因素如何,观察等待仍是标准治疗。

要点

  • 伊布替尼显著延迟早期CLL进展至症状性疾病,HR 0.276(95%CI 0.188-0.407),P<.001。
  • 中位观察69.3个月,26例死亡,伊布替尼组与安慰剂组总生存无显著差异(P=.562)。
  • 伊布替尼组心血管毒性增加,两组不良事件发生率分别为99.4%和60%。

核心结论

  • 伊布替尼治疗早期CLL较安慰剂延迟疾病进展,但在既定观察时间和少数死亡事件下未证实生存获益。
  • 在靶向治疗时代,无论风险因素如何,观察等待仍是标准治疗。

研究设计与样本

  • 德国CLL研究组开展随机、双盲、安慰剂对照III期试验。
  • 363例无症状、初治Binet A期CLL且进展风险增加的患者随机接受伊布替尼420mg/日(n=182)或安慰剂(n=181)。
  • 另152例低危患者分配至观察等待组。
  • 最终分析包括无事件生存、无进展生存、至下次治疗时间、总生存和安全性评估。

主要发现

  • 伊布替尼显著延迟进展至症状性疾病(P<.001;HR 0.276 [95%CI 0.188-0.407])。
  • 中位观察69.3个月时共26例死亡,未观察到生存获益(P=.562)。
  • 5年生存率:伊布替尼组93.3%(95%CI 89.3-97.3),安慰剂组93.6%(95%CI 89.5-97.7),观察等待组97.9%(95%CI 95.6-100)。
  • 自诊断起估算10年生存率:安慰剂组86.5%(95%CI 78.7-94.3),伊布替尼组89.8%(95%CI 83.3-96.3),观察等待组95.3%(95%CI 91.1-99.4)。
  • 伊布替尼组12例死亡中1例与CLL相关,安慰剂组14例死亡中4例死于CLL进展或Richter转化。

临床怎么用

  • 原文结论认为观察等待仍是早期CLL的标准治疗,无论风险因素如何。
  • 原文未据此给出伊布替尼用于早期CLL的推荐。

局限性

  • 在既定观察时间和少数死亡事件下,未证实生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. METHODS: The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression to receive ibrutinib (n = 182) at a daily dose of 420 mg or placebo (n = 181). Additionally, 152 low-risk patients were allocated to the watch-and-wait group. The final analysis included event-free survival, progression-free survival, time to next treatment, overall survival, and safety assessments. RESULTS: Ibrutinib significantly delayed progression to symptomatic disease (P < .001; hazard ratio, 0.276 [95% CI, 0.188 to 0.407]), but no survival benefit was observed with 26 death cases (P = .562) at a median observation time of 69.3 months. Five-year survival rates were excellent: 93.3% (95% CI, 89.3 to 97.3) in the ibrutinib group, 93.6% (95% CI, 89.5 to 97.7) in the placebo group, and 97.9% (95% CI, 95.6 to 100) in the watch-and-wait cohort. Estimated 10-year survival rates from diagnosis were 86.5% (95% CI, 78.7 to 94.3, placebo), 89.8% (95% CI, 83.3 to 96.3, ibrutinib), and 95.3% (95% CI, 91.1 to 99.4, watch and wait). In the ibrutinib group, one of 12 deaths was CLL-associated, compared with four of 14 fatal cases of CLL progression or Richter transformation in the placebo group. Adverse and serious adverse events occurred in 99.4% and 60% of both treatment groups, respectively. The safety profile indicated increased cardiovascular toxicity in the ibrutinib group. CONCLUSION: Ibrutinib treatment in early-stage CLL delayed disease progression compared with placebo. However, with the given observation time and few deaths, no survival benefit was demonstrated. In the era of targeted therapies, watch and wait remains the standard of care irrespective of risk factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Langerbeins P, Robrecht S, Nieper P, et al. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. J Clin Oncol. 2024. PMID: 39602678. doi:10.1200/JCO.24.00975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。